In a research report released earlier today, Cantor analyst Mara Goldstein maintained a Buy rating on shares of Celldex Therapeutics, Inc. (NASDAQ:CLDX), but reduced the …
Shake Shack Inc (NYSE:SHAK) increased 7.87% in pre-market trading to $76.
Celldex Therapeutics, Inc. (NASDAQ:CLDX) reported business and financial highlights for the second quarter ended June 30, 2015.
Oppenheimer analyst Christopher Marai offered some of his opinions on Celldex Therapeutics, Inc. (NASDAQ:CLDX) following a DSMB recommendation to continue the ongoing P3 trial (ACT-IV) …
Recently, various executives have taken part in insider selling activity for the stocks of Bank of America Corp (NYSE:BAC), QUALCOMM, Inc. (NASDAQ:QCOM), Celldex Therapeutics, …
Celldex Therapeutics, Inc. (NASDAQ:CLDX) price target has been raised by research analyst Stephen Brozak at WBB Securities.
Celldex Therapeutics, Inc. (NASDAQ:CLDX) shares were up more than 10% in pre-market trading today after the biopharmaceutical company released positive trial results from the …
Celldex Therapeutics, Inc. (NASDAQ:CLDX) shares rose more than +10% in pre-market trading to $32.
Celldex Therapeutics, Inc. (NASDAQ:CLDX), announced that several clinical programs, including the Phase 2 ReACT study of RINTEGA® (rindopepimut) in patients with recurrent glioblastoma (GBM), …
Brean Capital analyst Jonathan Aschoff came out with a few insights on Celldex Therapeutics (NASDAQ:CLDX) following the company’s first-quarter financial results and update on its …
